Dr. George Ansstas, MD

Dr. Ansstas practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Ansstas' NPI, 1790988053, was assigned on June 6, 2007. Dr. Ansstas holds Missouri license 2007026336.

Dr. Ansstas' primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Ansstas also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Ansstas' primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Ansstas is also affiliated with Missouri Baptist Medical Center. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Ansstas to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ansstas practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Ansstas' primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Ansstas is licensed in Missouri.

CMS data shows 1,580 Medicare services from Dr. Ansstas across 17 procedure codes in 2024, for 294 Medicare patients. Medicare paid $51,487 for them.

CMS counts 294 Medicare patients who saw Dr. Ansstas in 2024. The largest group is 65 to 74, with 140 patients. 74% of them have high blood pressure, and 72% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ansstas' median patient age at 73, with 38% women.

In 2024, Dr. Ansstas wrote 707 Medicare Part D claims for 113 patients. 73% of them were for generic drugs. CMS names the drug for 540 of them, across 17 drugs with 11 or more claims each, at $1,350,560 in total drug cost. In 2023, CMS named 507 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Ansstas for performance year 2024, reported as part of a group. Dr. Ansstas accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 51 papers to Dr. Ansstas, published from 2012 to 2024. 2021 was the busiest year, with 10. The most frequent topics are Melanoma, Brain Neoplasms and Immunotherapy. Dr. Ansstas has published most often in J Natl Compr Canc Netw. Dr. Ansstas' most frequent co-authors are Karam Khaddour, MD, Omar Hameed Butt, MD and Tanner Michael Johanns, MD.

Dmand AI links Dr. Ansstas to 10 clinical trials, 5 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Astrocytoma, Carcinoma, Basosquamous and Carcinoma, Merkel Cell. National Cancer Institute (NCI) sponsors the most, 6. Open Payments lists research payments to Dr. Ansstas that name 1 trial.

CMS Open Payments shows 376 general payments to Dr. Ansstas from 25 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 33% of the total. Novocure Inc. paid the most, $53,411. It also lists 23 research payments totaling $4,069 from 2021 to 2024, naming 1 clinical trial.